While the effects on TNFα were modest, as were those on IL-22, they need to be further explored to determine if the effects are a cause for concern with potential MS therapies, or the mechanism can be further exploited with more potent RORα inverse agonists for IBD. This evidence concerns the gene TNF and inflammatory bowel disease.